Dipeptidyl peptidase IV inhibitors as novel regulators of vascular disease

Vascular Pharmacology

Volumn 96-98, Issue , 2017, Pages 1-4

  Akoumianakis, Ioannis ^a   Antoniades, Charalambos ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Atherosclerosis; DPP IV inhibitors; Oxidative stress; Perivascular adipose tissue

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; INTERLEUKIN 10; LIRAGLUTIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SCLEROPROTEIN; STROMAL CELL DERIVED FACTOR 1; TENELIGLIPTIN; TUMOR NECROSIS FACTOR; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CARDIOVASCULAR AGENT; DIPEPTIDYL PEPTIDASE IV; DPP4 PROTEIN, HUMAN;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; INFLAMMATION; LEUKOCYTE ACTIVATION; LEUKOCYTE MIGRATION; OXIDATIVE STRESS; PERIVASCULAR ADIPOSE TISSUE; PHARMACEUTICAL CARE; PRIORITY JOURNAL; REVIEW; VASCULAR DISEASE; ADIPOSE TISSUE; ANIMAL; BLOOD VESSEL; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ADIPOSE TISSUE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; ATHEROSCLEROSIS; BLOOD VESSELS; CARDIOVASCULAR AGENTS; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 85026203865     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2017.07.001     Document Type: Review

References (50)

1. Beckman, J.A., Creager, M.A., Vascular complications of diabetes. Circ. Res. 118:11 (2016), 1771–1785.
2. Antonopoulos, A.S., Oikonomou, E.K., Antoniades, C., Tousoulis, D., From the BMI paradox to the obesity paradox: the obesity-mortality association in coronary heart disease. Obes. Rev. 17:10 (2016), 989–1000.
3. p.-d. Task Force on diabetes, C. cardiovascular diseases of the European Society of, D. European Association for the Study of, Ryden, L., Grant, P.J., Anker, S.D., Berne, C., Cosentino, F., Danchin, N., Deaton, C., Escaned, J., Hammes, H.P., Huikuri, H., Marre, M., Marx, N., Mellbin, L., Ostergren, J., Patrono, C., Seferovic, P., Uva, M.S., Taskinen, M.R., Tendera, M., Tuomilehto, J., Valensi, P., Zamorano, J.L., ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - summary. Diab. Vasc. Dis. Res. 11:3 (2014), 133–173.
4. Mannucci, E., Giannini, S., Dicembrini, I., Cardiovascular effects of basal insulins. Drug. Healthc Patient Saf. 7 (2015), 113–120.
5. Dicker, D., DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors. Diabetes Care 34:Suppl. 2 (2011), S276–S278.
6. Zhong, J., Rao, X., Rajagopalan, S., An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. Atherosclerosis 226:2 (2013), 305–314.
7. Fadini, G.P., Avogaro, A., Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vasc. Pharmacol. 55:1–3 (2011), 10–16.
8. Badimon, L., Cubedo, J., Adipose tissue depots and inflammation: effects on plasticity and resident mesenchymal stem cell function. Cardiovasc. Res., 2017.
9. Vilahur, G., Ben-Aicha, S., Badimon, L., New insights into the role of adipose tissue in thrombosis. Cardiovasc. Res., 2017.
10. Sorop, O., Olver, T.D., van de Wouw, J., Heinonen, I., van Duin, R.W., Duncker, D.J., Merkus, D., The microcirculation: a key player in obesity-associated cardiovascular disease. Cardiovasc. Res., 2017.
11. Antonopoulos, A.S., Antoniades, C., The role of epicardial adipose tissue in cardiac biology: classic concepts and emerging roles. J. Physiol., 2017.
12. Lamers, D., Famulla, S., Wronkowitz, N., Hartwig, S., Lehr, S., Ouwens, D.M., Eckardt, K., Kaufman, J.M., Ryden, M., Muller, S., Hanisch, F.G., Ruige, J., Arner, P., Sell, H., Eckel, J., Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 60:7 (2011), 1917–1925.
13. Ussher, J.R., Drucker, D.J., Cardiovascular biology of the incretin system. Endocr. Rev. 33:2 (2012), 187–215.
14. Trujillo, J.M., Nuffer, W., Ellis, S.L., GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther. Adv. Endocrinol. Metab. 6:1 (2015), 19–28.
15. Lambeir, A.M., Durinx, C., Scharpe, S., De Meester, I., Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit. Rev. Clin. Lab. Sci. 40:3 (2003), 209–294.
16. Zhong, J., Rao, X., Deiuliis, J., Braunstein, Z., Narula, V., Hazey, J., Mikami, D., Needleman, B., Satoskar, A.R., Rajagopalan, S., A potential role for dendritic cell/macrophage-expressing DPP4 in obesity-induced visceral inflammation. Diabetes 62:1 (2013), 149–157.
17. Solini, A., Rossi, C., Duranti, E., Taddei, S., Natali, A., Virdis, A., Saxagliptin prevents vascular remodeling and oxidative stress in db/db mice. Role of endothelial nitric oxide synthase uncoupling and cyclooxygenase. Vasc. Pharmacol. 76 (2016), 62–71.
18. Shiraki, A., Oyama, J., Komoda, H., Asaka, M., Komatsu, A., Sakuma, M., Kodama, K., Sakamoto, Y., Kotooka, N., Hirase, T., Node, K., The glucagon-like peptide 1 analog liraglutide reduces TNF-alpha-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis 221:2 (2012), 375–382.
19. Ban, K., Noyan-Ashraf, M.H., Hoefer, J., Bolz, S.S., Drucker, D.J., Husain, M., Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117:18 (2008), 2340–2350.
20. Okerson, T., Chilton, R.J., The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc. Ther. 30:3 (2012), e146–e155.
21. Antonopoulos, A.S., Margaritis, M., Coutinho, P., Digby, J., Patel, R., Psarros, C., Ntusi, N., Karamitsos, T.D., Lee, R., De Silva, R., Petrou, M., Sayeed, R., Demosthenous, M., Bakogiannis, C., Wordsworth, P.B., Tousoulis, D., Neubauer, S., Channon, K.M., Antoniades, C., Reciprocal effects of systemic inflammation and brain natriuretic peptide on adiponectin biosynthesis in adipose tissue of patients with ischemic heart disease. Arterioscler. Thromb. Vasc. Biol. 34:9 (2014), 2151–2159.
22. Margaritis, M., Antonopoulos, A.S., Digby, J., Lee, R., Reilly, S., Coutinho, P., Shirodaria, C., Sayeed, R., Petrou, M., De Silva, R., Jalilzadeh, S., Demosthenous, M., Bakogiannis, C., Tousoulis, D., Stefanadis, C., Choudhury, R.P., Casadei, B., Channon, K.M., Antoniades, C., Interactions between vascular wall and perivascular adipose tissue reveal novel roles for adiponectin in the regulation of endothelial nitric oxide synthase function in human vessels. Circulation 127:22 (2013), 2209–2221.
23. Woodward, L., Akoumianakis, I., Antoniades, C., Unravelling the adiponectin paradox: novel roles of adiponectin in the regulation of cardiovascular disease. Br. J. Pharmacol., 2016.
24. Akoumianakis, I., Tarun, A., Antoniades, C., Perivascular adipose tissue as a regulator of vascular disease pathogenesis: identifying novel therapeutic targets. Br. J. Pharmacol., 2016.
25. Akoumianakis, I., Antoniades, C., The interplay between adipose tissue and the cardiovascular system: is fat always bad?. Cardiovasc. Res., 2017.
26. Abu Bakar, H., Dunn, W.R., Daly, C., Ralevic, V., Sensory innervation of perivascular adipose tissue: a crucial role in artery vasodilatation and leptin release. Cardiovasc. Res., 2017.
27. Shirakawa, J., Fujii, H., Ohnuma, K., Sato, K., Ito, Y., Kaji, M., Sakamoto, E., Koganei, M., Sasaki, H., Nagashima, Y., Amo, K., Aoki, K., Morimoto, C., Takeda, E., Terauchi, Y., Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes 60:4 (2011), 1246–1257.
28. Dobrian, A.D., Ma, Q., Lindsay, J.W., Leone, K.A., Ma, K., Coben, J., Galkina, E.V., Nadler, J.L., Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice. Am. J. Physiol. Endocrinol. Metab. 300:2 (2011), E410–E421.
29. Icli, B., Feinberg, M.W., MicroRNAs in dysfunctional adipose tissue: cardiovascular implications. Cardiovasc. Res., 2017.
30. Kos, K., Baker, A.R., Jernas, M., Harte, A.L., Clapham, J.C., O'Hare, J.P., Carlsson, L., Kumar, S., McTernan, P.G., DPP-IV inhibition enhances the antilipolytic action of NPY in human adipose tissue. Diabetes Obes. Metab. 11:4 (2009), 285–292.
31. Meier, J.J., GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat. Rev. Endocrinol. 8:12 (2012), 728–742.
32. Kim Chung, T., Le, T. Hosaka, Yoshida, M., Harada, N., Sakaue, H., Sakai, T., Nakaya, Y., Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. Biochem. Biophys. Res. Commun. 390:3 (2009), 613–618.
33. Shiraishi, D., Fujiwara, Y., Komohara, Y., Mizuta, H., Takeya, M., Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation. Biochem. Biophys. Res. Commun. 425:2 (2012), 304–308.
34. Salim, H.M., Fukuda, D., Higashikuni, Y., Tanaka, K., Hirata, Y., Yagi, S., Soeki, T., Shimabukuro, M., Sata, M., Teneligliptin, a dipeptidyl peptidase-4 inhibitor, attenuated pro-inflammatory phenotype of perivascular adipose tissue and inhibited atherogenesis in normoglycemic apolipoprotein-E-deficient mice. Vasc. Pharmacol., 2017.
35. Alam, M.A., Chowdhury, M.R., Jain, P., Sagor, M.A., Reza, H.M., DPP-4 inhibitor sitagliptin prevents inflammation and oxidative stress of heart and kidney in two kidney and one clip (2K1C) rats. Diabetol. Metab. Syndr., 7, 2015, 107.
36. Liu, L., Liu, J., Tian, X.Y., Wong, W.T., Lau, C.W., Xu, A., Xu, G., Ng, C.F., Yao, X., Gao, Y., Huang, Y., Uncoupling protein-2 mediates DPP-4 inhibitor-induced restoration of endothelial function in hypertension through reducing oxidative stress. Antioxid. Redox Signal. 21:11 (2014), 1571–1581.
37. Salheen, S.M., Panchapakesan, U., Pollock, C.A., Woodman, O.L., The dipeptidyl peptidase-4 inhibitor linagliptin preserves endothelial function in mesenteric arteries from type 1 diabetic rats without decreasing plasma glucose. PLoS One, 10(11), 2015, e0143941.
38. Pujadas, G., De Nigris, V., Prattichizzo, F., La Sala, L., Testa, R., Ceriello, A., The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory. Endocrine, 2016.
39. Koibuchi, N., Hasegawa, Y., Katayama, T., Toyama, K., Uekawa, K., Sueta, D., Kusaka, H., Ma, M., Nakagawa, T., Lin, B., Kim-Mitsuyama, S., DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure. Cardiovasc. Diabetol., 13, 2014, 157.
40. Takai, S., Sakonjo, H., Jin, D., Significance of vascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats. J. Pharmacol. Sci. 125:4 (2014), 386–393.
41. Antonopoulos, A.S., Tousoulis, D., The molecular mechanisms of obesity paradox. Cardiovasc. Res., 2017.
42. Zeng, Y., Li, C., Guan, M., Zheng, Z., Li, J., Xu, W., Wang, L., He, F., Xue, Y., The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms. Cardiovasc. Diabetol., 13, 2014, 32.
43. Ervinna, N., Mita, T., Yasunari, E., Azuma, K., Tanaka, R., Fujimura, S., Sukmawati, D., Nomiyama, T., Kanazawa, A., Kawamori, R., Fujitani, Y., Watada, H., Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice. Endocrinology 154:3 (2013), 1260–1270.
44. Scheen, A.J., Cardiovascular effects of gliptins. Nat. Rev. Cardiol. 10:2 (2013), 73–84.
45. Green, J.B., Bethel, M.A., Armstrong, P.W., Buse, J.B., Engel, S.S., Garg, J., Josse, R., Kaufman, K.D., Koglin, J., Korn, S., Lachin, J.M., McGuire, D.K., Pencina, M.J., Standl, E., Stein, P.P., Suryawanshi, S., Van de Werf, F., Peterson, E.D., Holman, R.R., T.S. Group, Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 373:3 (2015), 232–242.
46. Scirica, B.M., Bhatt, D.L., Braunwald, E., Steg, P.G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S.D., Hoffman, E.B., Cavender, M.A., Udell, J.A., Desai, N.R., Mosenzon, O., McGuire, D.K., Ray, K.K., Leiter, L.A., Raz, I., Committee, S.-T.S., Investigators, saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 369:14 (2013), 1317–1326.
47. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F., Nauck, M.A., Nissen, S.E., Pocock, S., Poulter, N.R., Ravn, L.S., Steinberg, W.M., Stockner, M., Zinman, B., Bergenstal, R.M., Buse, J.B., Committee, L.S., Investigators, L.T., Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375:4 (2016), 311–322.
48. Mannucci, E., Mosenzon, O., Avogaro, A., Analyses of results from cardiovascular safety trials with DPP-4 inhibitors: cardiovascular outcomes, predefined safety outcomes, and pooled analysis and meta-analysis. Diabetes Care 39:Suppl. 2 (2016), S196–S204.
49. Abbas, A.S., Dehbi, H.M., Ray, K.K., Cardiovascular and non-cardiovascular safety of dipeptidyl peptidase-4 inhibition: a meta-analysis of randomized controlled cardiovascular outcome trials. Diabetes Obes. Metab. 18:3 (2016), 295–299.
50. Clifton, P., Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?. Clin. Ther. 36:12 (2014), 2072–2079.